Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
| ▸ | HCAR2 | Q8TDS4 | 3/20 | 0.46 |
| ▸ | TSHR | P16473 | 5/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | NAAA | Q02083 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | ESR1 | P03372 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.38 |
| ▸ | RNASEL | Q05823 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | ACHE | P22303 | 6/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16114719 | 1.00 | ALDH1A1 (0.50) | ALDH1A1ATMHCAR2TSHRHPGD | |
| SCHEMBL1971178 | 1.00 | ALDH1A1 (0.50) | ALDH1A1ATMHCAR2TSHRHPGD | |
| SCHEMBL15865201 | 0.94 | NAAA (0.48) | ALDH1A1ATMHCAR2TSHRNAAA | |
| SCHEMBL15864900 | 0.92 | NAAA (0.52) | ALDH1A1HCAR2TSHRNAAAEPHX1 | |
| SCHEMBL15864530 | 0.92 | NAAA (0.52) | ALDH1A1HCAR2TSHRNAAAEPHX1 | |
| SCHEMBL15864524 | 0.92 | NAAA (0.52) | ALDH1A1HCAR2TSHRNAAAEPHX1 | |
| SCHEMBL843522 | 0.91 | ALDH1A1 (0.58) | ALDH1A1ATMHCAR2TSHRHPGD | |
| SCHEMBL158105 | 0.91 | ALDH1A1 (0.58) | ALDH1A1ATMHCAR2TSHRHPGD | |
| SCHEMBL15843513 | 0.87 | ALDH1A1 (0.54) | ALDH1A1ATMHCAR2TSHRHPGD | |
| SCHEMBL15843351 | 0.87 | ALDH1A1 (0.54) | ALDH1A1ATMHCAR2TSHRHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 434 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4326709-A1 | METHODS OF SYNTHESIZING LIPSTATIN DERIVATIVES | Panafina, Inc. (US) | 2024-02-28 | — | — | EP | claimed |
| CN-111056968-B | Preparation method of benorilate | 广西科技大学 | 2023-04-14 | — | — | CN | claimed |
| EP-3606922-A1 | CONJUGATION OF A CYTOTOXIC DRUG WITH BIS-LINKAGE | Hangzhou Dac Biotech Co., Ltd (CN) | 2020-02-12 | — | — | EP | claimed |
| WO-2018185526-A1 | CONJUGATION OF A CYTOTOXIC DRUG WITH BIS-LINKAGE | HANGZHOU DAC BIOTECH CO., LTD (CN) | 2018-10-11 | — | — | WO | claimed |
| EP-3337789-A1 | PROCESS FOR PREPARATION OF VORTIOXETINE HYDROBROMIDE | Amneal Pharmaceuticals Company GmbH (CH) | 2018-06-27 | — | — | EP | claimed |
| WO-2017029377-A1 | PROCESS FOR PREPARATION OF VORTIOXETINE HYDROBROMIDE | AMNEAL PHARMACEUTICALS COMPANY GMBH (CH) | 2017-02-23 | — | — | WO | claimed |
| WO-2014108795-A2 | AN IMPROVED PROCESS FOR THE PREPARATION OF CHIRAL DIOL SULFONES AND STATINS | AUROBINDO PHARMA LIMITED (IN) | 2014-07-17 | — | — | WO | claimed |
| WO-2013072903-A1 | NITROIMIDAZOXADIAZOCINE COMPOUNDS | ITHEMBA PHARMACEUTICALS (PROPRIETARY) LIMITED (ZA) | 2013-05-23 | — | — | WO | claimed |
| EP-2560939-A2 | NOVEL PROCESS FOR PREPARING PHENYLCYCLOPROPYLAMINE DERIVATIVES USING NOVEL INTERMEDIATES | Actavis Group Ptc Ehf (IS) | 2013-02-27 | — | — | EP | claimed |
| WO-2011132083-A2 | NOVEL PROCESS FOR PREPARING PHENYLCYCLOPROPYLAMINE DERIVATIVES USING NOVEL INTERMEDIATES | ACTAVIS GROUP PTC EHF (IS) | 2011-10-27 | — | — | WO | claimed |
| EP-1758866-A1 | PROCESSES FOR PREPARING 6-ALKYL-5-ARYLSULFONYL- DIHYDROPHENANTHRIDINES | Wyeth (US) | 2007-03-07 | — | — | EP | claimed |
| WO-2006009831-A1 | PROCESSES FOR PREPARING 6-ALKYL-5-ARYLSULFONYL- DIHYDROPHENANTHRIDINES | WYETH (US) | 2006-01-26 | — | — | WO | claimed |
| WO-2000001678-A1 | PROCESS FOR THE SYNTHESIS OF SUBSTITUTED PIPERAZINONES VIA MITSUNOBU REACTION | MERCK & CO., INC. (US) | 2000-01-13 | — | — | WO | claimed |
| US-20250011326-A1 | FUSED HETEROCYCLIC DERIVATIVES AND THEIR USE IN THE TREATMENT OF HBV INFECTION | Janssen Sciences Ireland Unlimited Company (IE) | 2025-01-09 | — | — | US | disclosed |
| WO-2024112746-A1 | PROCESSES AND INTERMEDIATES FOR THE PREPARATION OF A PYRIMIDINE AMINOPYRAZOLE COMPOUND | DENALI THERAPEUTICS INC. (US) | 2024-05-30 | — | — | WO | disclosed |
| EP-4373817-A1 | SUBSTITUTED PYRAZINE-2-CARBOXAMIDES AS HPK1 INHIBITORS FOR THE TREATMENT OF CANCER | Astrazeneca AB (SE) | 2024-05-29 | — | — | EP | disclosed |
| EP-0873340-A1 | HETEROCYCLIC SUBSTITUTED CYCLOPENTANE COMPOUNDS | Abbott Laboratories (US) | 1998-10-28 | — | — | EP | disclosed |
| WO-1996040686-A1 | HETEROCYCLIC SUBSTITUTED CYCLOPENTANE COMPOUNDS | ABBOTT LABORATORIES (US) | 1996-12-19 | — | — | WO | disclosed |
| WO-1995003300-A1 | HETEROARYL QUINOLINES AS INHIBITORS OF LEUKOTRIENE BIOSYNTHESIS | MERCK FROSST CANADA INC. (CA) | 1995-02-02 | — | — | WO | disclosed |
| WO-1994005657-A1 | HETEROARYLNAPHTHALENE HYDROXY ACIDS AS INHIBITORS OF LEUKOTRIENE BIOSYNTHESIS | MERCK FROSST CANADA INC. (CA) | 1994-03-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250011326-A1 | FUSED HETEROCYCLIC DERIVATIVES AND THEIR USE IN THE TREATMENT OF HBV INFECTION | HAVCR2, HCCS, HDGF | ALDH1A1 3167/4885ATM 3579/4885HCAR2 1246/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.